Clinical Manifestations and Myositis-Specific Autoantibodies Associated with Physical Dysfunction after Treatment in Polymyositis and Dermatomyositis: An Observational Study of Physical Dysfunction with Myositis in Japan
Table 1
Clinical characteristics of the enrolled PM/DM patients.
()
Age at disease onset, median years
46 (37–58)
Female, number (%)
61 (79)
PM, DM, CADM, number
40, 30, 7
Duration from disease onset to initiation of treatment, median months
3 (2–8)
Duration from disease onset to enrolment in this study, median months
105 (46–143)
Complications at first visit, number (%)
Interstitial lung disease
52 (68)
Cardiomyopathy
13 (17)
Malignancy
3 (4)
Myositis-specific autoantibodies, number (%)
Anti-ARS
22 (29)
Anti-MDA5
7 (9)
Anti-Mi-2
2 (3)
Anti-NXP-2
2 (3)
Anti-SRP
9 (12)
Anti-TIF1-
4 (5)
Myositis-associated autoantibodies, number (%)
Anti-Ku
3 (4)
Anti-U1-snRNP
10 (13)
Anti-SS-A
30 (39)
Treatment
Initial dosage of PSL, median mg/day
50 (40–60)
Administration of immunosuppressant agents, number (%)
